Aptahem
BioStock article: Aptahem gives update on operations and rights issue
Read the interview with Aptahem's CEO Mikael Lindstam at biostock.se:
https://www.biostock.se/en/2023/06/aptahem-gives-update-on-operations-and-rights-issue/
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.
Datum | 2023-06-21, kl 09:01 |
Källa | Cision |
![](https://static.allaaktier.se/ads/hand-waving-2.png)